Abstract
Cardiometabolic risk factors, such as hypercholesterolemia, hypertriglyceridemia, metabolic syndrome, diabetes, and arterial hypertension, are major predictors of the premature development of cardiovascular diseases (CVD). Since CVD prevention needs a life-course approach, beyond dietary and pharmacological treatment, non-pharmacological treatment should be considered an important alternative for patients in primary prevention with mild–moderate cardiometabolic risk factors at low-moderate global risk of CVD. Several functional foods and nutraceuticals are efficacious, safe and well tolerated. However, only some (monacolins of red yeast rice and omega-3 fatty acids) have showed, in long-term randomized clinical trials, a reduction of cardiovascular events.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stamler J, Wentworth D, Neaton JD, for MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous or graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc. 1986;256:2823–8.
Giudice R, Izzo R, Manzi MV, et al. Lifestyle-related risk factors, smoking status and cardiovascular disease. High Blood Press Cardiovasc Prev. 2012;19:85–92.
Lichtenstein AH. Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res. 2006;47:1661–7.
Baigen TC, Blackwell L, Emberson J, Cholesterol Treatment Trialists’ (CTT) Collaboration, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585–91.
Volpe R, Angelico F, Arca M, et al. In: Gotto AM, Mancini M, Richter WO, Schwandt P, editors. Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease: Effects of simple dietary advice on serum lipids in severe and moderate primary hypercholesterolemia. Basel: Karger; 1992. p. 226–30.
Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: I and II. JAMA. 1984;1984(251):351–74.
Frick MH, Eb O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237–45.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with Pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–7.
Volpe R, Cicero AFG. In: Milei J, Ambrosio G, editors. Recent advance in cardiology: non-pharmacological treatment of hypercholesterolemia. New York: Nova Science Publishers Inc; 2014. pp. 25–54.
Wilburn AJ, King DS, Glisson J, et al. The natural treatment of hypertension. J Clin Hypertens. 2004;6:242–8.
Davi G, Santilli F, Patrono C. Nutraceutical in diabetes and metabolic syndrome. Cardiovasc Ther. 2010;4:216–26. doi:10.1111/j.1755-5922.2010.00179.x.
Cicero AF, Borghi C. Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals. Curr Hypertens Rep. 2013;15:260–7.
Izzo R, de Simone G, Giudice R, Chinali M, Trimarco V, De Luca N, Trimarco B. Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia. J Hypertens. 2010;28:1482–7.
Cicero AF, Tartagni E, Ertek S. Nutraceuticals for metabolic syndrome management: from laboratory to benchside. Curr Vasc Pharmacol. 2014;12:565–71.
Catapano AL, Reiner Z, De Backer G, et al. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:3–46.
Covas MI. Olive oil and the cardiovascular system. Pharmacol Res. 2007;55:175–86.
Lu Z, Kou W, Du B, et al. Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689–93.
Valagussa F, Franzosi MG, Geraci E, et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. Lancet. 1999;354:447–55.
Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr. 2012;107(suppl2):201–13.
Giampaoli S, Palmieri L, Chiodini P, et al. The Italian charter of the global cardiovascular risk. It Heart J. 2004;5(suppl):177–85.
Cicero AF, De Sando V, Izzo R, et al. Effect of a combined nutraceutical containing Orthosiphon stamineus effect on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: a randomized clinical trial. Complement Ther Clin Pract. 2012;18:190–4.
Author information
Authors and Affiliations
Corresponding author
Additional information
XXXI National Congress of the Italian Society of Hypertension (SIIA), Bologna, October 09–11 2014.
Symposium: Nutraceutical approach for blood pressure control.
Rights and permissions
About this article
Cite this article
Volpe, R., Sotis, G. Nutraceuticals: Definition and Epidemiological Rationale for Their Use in Clinical Practice. High Blood Press Cardiovasc Prev 22, 199–201 (2015). https://doi.org/10.1007/s40292-015-0092-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40292-015-0092-5